Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

August 31, 2008

Study Completion Date

November 1, 2014

Conditions
Graft Versus Host Disease
Interventions
DRUG

pentostatin

4 mg/sq m IV infusion over 20-30 min q 2 weeks

Trial Locations (16)

10021

New York Weill Cornell Cancer Center at Cornell University, New York

19713

CCOP - Christiana Care Health Services, Newark

19958

Tunnell Cancer Center at Beebe Medical Center, Lewes

21201

Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore

21921

Union Hospital Cancer Program at Union Hospital, Elkton

27710

Duke Comprehensive Cancer Center, Durham

55905

Mayo Clinic Cancer Center, Rochester

60612-7243

University of Illinois Cancer Center, Chicago

60637-1470

University of Chicago Cancer Research Center, Chicago

08043

Cancer Institute of New Jersey at Cooper - Voorhees, Voorhees Township

27157-1096

Wake Forest University Comprehensive Cancer Center, Winston-Salem

43210-1240

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus

19104-4283

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

19111-2497

Fox Chase Cancer Center - Philadelphia, Philadelphia

15224-1791

Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital, Pittsburgh

23298-0037

Virginia Commonwealth University Massey Cancer Center, Richmond

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00074035 - Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease | Biotech Hunter | Biotech Hunter